As of May 23
| -0.04 / -1.21%|
The 6 analysts offering 12-month price forecasts for Array Biopharma Inc have a median target of 7.50, with a high estimate of 13.00 and a low estimate of 6.00. The median estimate represents a +129.36% increase from the last price of 3.27.
The current consensus among 7 polled investment analysts is to Buy stock in Array Biopharma Inc. This rating has held steady since May, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.